#Key Players in Dyslipidemia Therapeutics
Text
Navigating the Cardiovascular Landscape: Trends, Technologies, and Transformations
The cardiovascular field stands at the forefront of medical innovation, with dynamic growth in various sectors, including cardiovascular devices, drugs, diagnostics, and safety services. In this blog, we will explore the multifaceted landscape of the cardiovascular market, uncovering market trends, major players, and the pivotal role of technological advancements in reshaping cardiovascular healthcare.
Cardiovascular Devices Market: A Dynamic Frontier
Market Size and Demand:
The global cardiovascular devices market is undergoing significant expansion, with a projected valuation of USD 65.4 billion by 2025. This growth is propelled by a surge in demand for cutting-edge technologies aimed at addressing cardiovascular diseases, which remain a leading cause of morbidity and mortality worldwide.
Innovation Driving Market Dynamics:
Innovative cardiovascular devices, such as implantable cardioverter-defibrillators (ICDs), transcatheter heart valves, and wearable cardiac monitors, are redefining the landscape. The demand for these advanced technologies underscores the industry's commitment to providing more efficient and patient-friendly solutions.
Cardiovascular Drugs Market: A Pillar of Therapeutic Advancements
Market Size and Major Players:
The cardiovascular drugs market, valued at USD 83.95 billion in 2020, is anticipated to witness a compound annual growth rate (CAGR) of 4.3% from 2021 to 2028. Key players, including Pfizer, Novartis, and AstraZeneca, continue to drive innovation in pharmaceutical interventions for cardiovascular diseases, contributing significantly to market growth.
Focus on Cardiovascular Disease Drugs:
With an increasing prevalence of cardiovascular diseases, there is a growing focus on the development of drugs targeting specific cardiovascular conditions. This includes medications addressing hypertension, dyslipidemia, and heart failure, among others.
Cardiovascular Diagnostic Devices Market: Precision in Diagnosis
Market Research Reports and Industry Trends:
The cardiovascular diagnostic devices market is evolving rapidly, with a projected CAGR of 5.4% from 2021 to 2026. Comprehensive industry research reports highlight emerging trends such as the integration of artificial intelligence (AI) in diagnostic tools, offering precision and efficiency in cardiovascular disease diagnosis.
Cardiac Safety Services Market: Ensuring Patient Well-being
Ensuring Safety in Cardiovascular Therapies:
Cardiac safety services have become integral to the development and monitoring of cardiovascular drugs. These services play a crucial role in assessing and managing potential cardiac risks associated with pharmaceutical interventions, ensuring patient safety throughout the drug development process.
Cardiovascular Surgery Market: Advancing Surgical Interventions
Technological Innovations in Surgery:
The cardiovascular surgery market is witnessing transformative advancements, with minimally invasive procedures, robotic-assisted surgeries, and innovative surgical devices leading the way. These developments aim to enhance patient outcomes, reduce recovery times, and improve overall surgical experiences.
Conclusion: Navigating the Future of Cardiovascular Health
In conclusion, the cardiovascular landscape is undergoing a paradigm shift fueled by technological innovations, dynamic market trends, and the tireless efforts of industry leaders. As cardiovascular devices, drugs, and diagnostics continue to evolve, the collective goal remains clear – to improve patient outcomes, enhance diagnostic precision, and reduce the global burden of cardiovascular diseases. The collaborative efforts of major players, coupled with ongoing research and development, promise a future where cardiovascular health is at the forefront of medical progress.
#Cardiovascular Devices Market#Cardiovascular Drugs Market#Cardiac Safety Services Market#Cardiovascular Industry Research Reports#Top Cardiovascular Pharma Companies
1 note
·
View note
Text
0 notes
Link
The report name Dyslipidemia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
#Dyslipidemia pipeline review#Pharmaceutical and Healthcare disease pipeline#dyslipidemia treatment#Key Players in Dyslipidemia Therapeutics#Dyslipidemia Pipeline Overview#Dyslipidemia Pipeline Assessment#dyslipidemia pharmacology
0 notes
Text
Microalbuminuria Market - Wide range of applications and users by 2025
Global Microalbuminuria Market: Snapshot
Microalbuminuria is a condition that affects the kidney and restricts in retaining serum albumin, which is considered as a vital factor for the kidney to maintain its overall health of the body. The rising cases of obesity of diabetes across the globe have resulted in a significant rise in the microalbuminuria, which is likely to encourage the growth of the market in the next few years. The rising emphasis of the leading players on the research and development activities and development of new products are expected to encourage the growth of the global microalbuminuria market in the coming years.
Furthermore, the rising awareness among consumers regarding a healthy lifestyle and diet and the increasing disposable income are projected to supplement the growth of the global microalbuminuria market in the next few years. In addition, the expected entry of new players in order to gain a competitive edge are likely to focus on the expansion of the product portfolio, which is estimated to supplement the market’s growth in the near future. At present, several tests are available in the market, which helps in determining the condition of microalbuminuria. The emergence of effective drugs and therapeutics is projected to contribute towards the development of the overall market.
The rising expenditure and the availability of enhanced healthcare infrastructure in developed economies are expected to generate promising opportunities for key players operating in Europe and North America. Furthermore, the presence of several leading players in these two regions are anticipated to accelerate the growth of the global microalbuminuria market in the next few years. This market is estimated to witness a healthy growth in several developing economies across the globe.
Request Sample Copy of the Report @
https://www.tmrresearch.com/sample/sample?flag=B&rep_id=110
Global Microalbuminuria Market: Overview
Albumin is a commonly found protein in the blood and constitutes around 50% of the blood protein. Microalbuminuria refers to a condition in which kidney is not able to retain serum albumin, which is essential for the kidney to maintain overall health of the body, and exerts it in the urine. During certain conditions like diabetes, especially type 1 patients, nephropathy, and other nephrotic syndromes, the chances of microalbuminuria is escalated. A research by British Medical Journal on diabetic children with type 1 diabetes revealed that 26% of the all the diabetic children had microalbuminuria, of which nearly 48% of the children had persistent microalbuminuria which is highly likely to lead to further worsening of the conditions in a few years.
Though microalbuminuria can be treated in most causes with suitable treatment and medication along with dietary changes, certain cases can also be associated with high risk of ischemic heart disease. Consequently, routine monitoring and timely treatment of microalbuminuria is of utmost importance and as a result, the demand in the global microalbuminuria market is projected for a healthy growth rate during the forecast period of 2017 to 2025.
Request TOC of the Report @
https://www.tmrresearch.com/sample/sample?flag=T&rep_id=110
Global Microalbuminuria Market: Trends and Prospects
Elderly people are more prone to diabetic diseases. According to the National Institute of Aging (NIH), 524 million people were aged over 65 across the globe and this number is estimated to reach 1.5 billion, which will represent nearly 16% of the world’s population. Moreover, the World Health Organization (WHO), 422 million people suffered from some form of diabeties in 2014, and the number is expected to continue swelling in the near future. These rising numbers are the foremost drivers in the global market for microalbuminuria.
Research and development for the treatment of microalbuminuria is another factor that is expected to favor the expansion of the market. As of now, the treatment is broadly via dietary supplements, but some manufacturers are also coming up with low fat or albumin variants. Since cholesterol or dyslipidemia treatment have not shown any effect on albuminuria patients, possibility for therapy for microalbuminuria is huge, before it turns into cardiovascular diseases. Increased disposable income among the urban population is also expected to boost the microalbuminuria market in near future.
Read Comprehensive Overview of Report @
https://www.tmrresearch.com/microalbuminuria-market
Global Microalbuminuria Market: Regional Outlook
Geographically, the global microalbuminuria market can be divided into North America, Asia Pacific, Europe, South America, and rest of the world. Currently, North America serves the maximum demand due to robust healthcare infrastructure in the countries such as the U.S. and Canada. However, regional markets of South and East Asia, Europe, South America, and Africa are also expected to extend the demand during the forecast period due to high prevalence rate of diabetic patients in these regions.
Some of the key players currently operational in microalbuminuria market are Novartis AG, Sanofi, Alfa Wassermann S.p.A, Steno Diabetes Center A/S, Takeda Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company, AstraZeneca Plc, AbbVie Inc. , Fondazione Mario Negri Sud, and Daiichi Sankyo Company, Ltd.
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Contact:
TMR Research,
3739 Balboa St # 1097,
San Francisco, CA 94121
United States
Tel: +1-415-520-1050
Email: [email protected]
1 note
·
View note
Text
Global Region to Remain one of The Leading Outlook for Dyslipidemia Drugs Market Through 2028
Global Dyslipidemia Drugs Market, Geography (North America (United States, Canada and Mexico), South America (China, Japan, Korea, India and Southeast Asia), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), Middle East and Africa (Saudi Arabia, Egypt, Nigeria and South Africa)) Industry Trends 2021-2028
<strong>Market overview</strong>
This market report on Dyslipidemia Drugs can help the companies to make crucial business plans on production techniques, raw materials procurement, and to increase the industry chain cycle of the market globally. The case study report on Dyslipidemia Drugs is a brief history and a detailed assessment of the Dyslipidemia Drugs market 2021 including key company profiles, and overall competitive scenario, key market trends, upcoming technologies, industry drivers, challenges, regulatory policies.
<strong> Request a sample Report of Dyslipidemia Drugs Market @ <a href=https://www.statistifymarketresearch.com/reports/dyslipidemia-drugs-market/sample-request-87273>https://www.statistifymarketresearch.com/reports/dyslipidemia-drugs-market/sample-request-87273</a></strong>
<strong>Methodology</strong>
The research work involved the usage of both primary and secondary data sources. The research methods involved the study of many points affecting the industry, including government guidelines, market surroundings, combative landscape, past data. Primary and Secondary research are the two methods that are used for the survey purpose. The primary sources consist of having interviews with many industry experts, suppliers, and other specialists. The secondary sources consist of an analysis of empirical data from press releases, government-designed websites, yearly reports of the companies, and other related documents. Other fields of the examination are modern shifting in the market, technological invention, upcoming technologies, and the technical enhancement in related industries, market risks, opportunities, hindering, and risks in the operating market. The Data acquirement phase involves gathering and merging market information and data related with the help of various sources and research processes. Structured databases such as D&B Hoover and Bloomberg are used which helps to recognize the competitive environment of top market players along with profile details.
<strong>Regional Analysis</strong>
Any type of report on Dyslipidemia Drugs is a highly valuable and important tool for any business association regardless of the scale on which it operates in the sector. It provides a source to track and examine the performance and overall condition of the business while also identifying fields that has the scope for improvement for the better functioning of the organization. A well-prepared business report also holds great value as it suggests preventive measures that need to be done to avoid the business fails to meet the desired targets and thus helps to recover from the adversities. An annual report on Dyslipidemia Drugs prepared in the company is an effective tool for providing employees, investors, and other clients with a complete picture of their business.
<strong>Customization of the Report: </strong>
The customized report is provided by our consultancy at a reasonable price. We provide updated information according to the requirements of the customers in the market world.
<strong>Top Listed Companies in the Dyslipidemia Drugs Market Include</strong>
AstraZeneca,Bristol-Myers Squibb,Sanofi,Merck,Amgen,Pfizer,Cerenis,Amarin Corporation,Alnylam Pharmaceuticals,Catabasis Pharmaceuticals,Daiichi Sankyo,GlaxoSmithKline,Cipla,Kadmon Pharmaceuticals,Eli Lilly,Daewoong Pharmaceutical,CJ HealthCare,JW Pharmaceuticals,Esperion Therapeutics,CKD Bio,Lupin Pharmaceuticals
<strong>Reasons to buy this Report:</strong>
It helps in understanding the major key product segments.
This report throws on Dyslipidemia Drugs light on the dynamics of the market such as drivers, restraints, trends, and opportunities.
It offers the regional analysis of Dyslipidemia Drugs Market along with business profiles of several stakeholders in the research market.
It offers massive data about trending factors that will influence the progress of the Dyslipidemia Drugs Market.
It offers an in-depth analysis of the changing competitive scenario in the Dyslipidemia Drugs market of the research industry.
<strong>Request for Customization @ <a href=https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=87273>https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=87273</a></strong>
<strong>Benefits:</strong>
1. Well updated information.
2. Statistical report provided.
3. Discount offer in customization.
4. Service at the global level.
5. Company research report provided.
<strong>Services:</strong>
1. Expert analysts at your service.
2. Service according to your needs
3. Clearance of your queries.
4. Whole day service
5. Well updated Report.
<strong>Frequently Asked Questions?</strong>
Q1. What is the total market value of the Dyslipidemia Drugs market report?
Q2. What would be the forecast period in the Dyslipidemia Drugs market report?
Q3. What is the base year considered in the Dyslipidemia Drugs market report?
Q4. Which are the top companies hold the market share in the Dyslipidemia Drugs market ?
Q5. Which is expected to be the fastest growing segment in the Dyslipidemia Drugs market?
Q6. Which market holds the maximum market share of the Dyslipidemia Drugs market ?
Q7. How the company profile has been selected?
Q8. What will be the market value of the Dyslipidemia Drugs market in 2028?
<strong>Full Report Summary of Dyslipidemia Drugs Market @ <a href=https://www.statistifymarketresearch.com/dyslipidemia-drugs-market>https://www.statistifymarketresearch.com/dyslipidemia-drugs-market</a></strong>
<strong>About Statistify Market Research</strong>
Statistify Market Research is a market research organization that endeavors to furnish all clients with the most ideal help and suggestions. Our research is exceptionally intended for your associations working in all areas and assist them with investigating viable development techniques and proposals. We don't hold fast to a uniform rule. We comprehend that your organization has explicit research necessities, and we endeavor to comprehend the subtleties of your individual research needs so we can give you concentrated research administrations.
<strong>Company Name - Statistify Market Research</strong>
Office Address - 156, Sector 9 Vasundhra Aptts Rohini,
New Delhi 110085 IN
Telephone Numbers - (+44) 162-237-1047 (+44) 162-237-1047
Email ID - <a href="mailto:[email protected]"><strong>[email protected]</strong></a>
Contact Us – <a href="https://www.statistifymarketresearch.com/contact-us/"><strong>https://www.statistifymarketresearch.com/contact-us/</strong></a>
0 notes
Text
Dyslipidemia Drugs Market 2021 Global Industry Analysis by Trends, Size, Share, Company Overview, Growth and Forecast by 2027
"
Dyslipidemia Drugs Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.
Sample Copy of This Report:https://axelreports.com/request-sample/61500
A 360 degree outline of the competitive scenario of the Global Dyslipidemia Drugs Market is presented by Axel Reports Market Insights. It has a massive data allied to the recent product and technological developments in the markets.
It has a wide-ranging analysis of the impact of these advancements on the market’s future growth, wide-ranging analysis of these extensions on the market’s future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.
Reasons for buying this report:
It offers an analysis of changing competitive scenario.
For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.
It offers seven-year assessment of Global Dyslipidemia Drugs
It helps in understanding the major key product segments.
Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.
It offers regional analysis of Global Dyslipidemia Drugs Market along with business profiles of several stakeholders.
It offers massive data about trending factors that will influence the progress of the Global Dyslipidemia Drugs
Get ToC for the overview of the premium report @ https://axelreports.com/industry-analysis/2021-2027-global-and-regional-dyslipidem/61500
By Market Players:
AstraZeneca
Bristol-Myers Squibb
Sanofi
Merck
Amgen
Pfizer
Cerenis
Amarin Corporation
Alnylam Pharmaceuticals
Catabasis Pharmaceuticals
Daiichi Sankyo
GlaxoSmithKline
Cipla
Kadmon Pharmaceuticals
Eli Lilly
Daewoong Pharmaceutical
CJ HealthCare
JW Pharmaceuticals
Esperion Therapeutics
CKD Bio
Lupin Pharmaceuticals
By Type
Statins
Cholesterol absorption inhibitors
Dyslipidemia injectable
By Application
Hospitals and Clinics
Medical Laboratories
Drug Stores
Others
A detailed outline of the Global Dyslipidemia Drugs Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.
This is anticipated to drive the Global Dyslipidemia Drugs Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Dyslipidemia Drugs Market are currently adopting new technological trends in the market.
Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Dyslipidemia Drugs Market. The feasibility of the new report is also measured in this research report.
Make an Enquiry for purchasing this Report :https://axelreports.com/enquiry-before-buying/61500
Table of Contents:
Global Dyslipidemia Drugs Market Overview
Economic Impact on Industry
Market Competition by Manufacturers
Production, Revenue (Value) by Region
Production, Revenue (Value), Price Trend by Type
Market Analysis by Application
Cost Analysis
Industrial Chain, Sourcing Strategy and Downstream Buyers
Marketing Strategy Analysis, Distributors/Traders
Market Effect Factors Analysis
Global Dyslipidemia Drugs Market Forecast
ABOUT US:
Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.
Contact:
Axel Reports
Akansha G (Knowledge Partner)
Office No- B 201
Pune, Maharashtra 411060
Phone: US +18488639402
Email: [email protected]/
Web: https://axelreports.com/
"
0 notes
Text
Dyslipidemia Market Strategic Insights and key Business Influencing Factors | Major Players – Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals.
Dyslipidemia Market is a condition in which the levels of lipids (cholesterol, triglycerides, or both) or low high-density lipoprotein (HDL) cholesterol level elevated due to multiple reasons including lifestyle, genetics-disorders, drugs etc. According to World Health Organization, there were approximately 17.9 million people in 2016, who died from cardiovascular diseases, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.
Global Dyslipidemia is expected to rise gradually to an estimated value of USD 27.52 billion by 2026, registering a CAGR of 10.50% in the forecast period of 2019-2026 with the annual sales of USD 12.38 billion in the year of 2018. This rise in market value can be attributed to the increase in prevalence and awareness along with concerns regarding the health of patients.
Get Sample Report at :
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dyslipidemia-market
Competitive Analysis: Global Dyslipidemia Market
Few of the major competitors currently working in Global Dyslipidemia Market are AstraZeneca (UK), Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla Inc., CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, Lupin Pharmaceuticals and few among others.
Key Pointers Covered in the Global Dyslipidemia Market Trends and Forecast to 2026
Global Dyslipidemia Market New Sales Volumes
Global Dyslipidemia Market Replacement Sales Volumes
Global Dyslipidemia Market Installed Base
Global Dyslipidemia Market By Brands
Global Dyslipidemia Market Size
Global Dyslipidemia Market Procedure Volumes
Global Dyslipidemia Market Product Price Analysis
Global Dyslipidemia Market Healthcare Outcomes
Global Dyslipidemia Market Cost of Care Analysis
Global Dyslipidemia Market Regulatory Framework and Changes
Global Dyslipidemia Market Prices and Reimbursement Analysis
Global Dyslipidemia Market Shares in Different Regions
Recent Developments for Global Dyslipidemia Market Competitors
Global Dyslipidemia Market Upcoming Applications
Global Dyslipidemia Market Innovators Study
Get Detailed TOC:
https://www.databridgemarketresearch.com/toc/?dbmr=global-dyslipidemia-market
Key Developments in the Market:
In the year 2018, Sanofi and Regeneron Pharmaceuticals, Inc. announced that Praluent (alirocumab) in phase 3 clinical trialdemonstrated the risk of major adverse cardiovascular events (MACE) in patients who had suffered a recent acute coronary syndrome (ACS) event such as a heart attack.
In the year 2018, Amgen Inc. announced the launch of Repatha (Evolocumab) in the US for the indication of heart attacks and stroke due to high cholesterol at a reduced price to gain more customers.
In the year 2015, WuXi PharmaTech announced its partnership with Eli Lilly to develop, manufacture, and commercializes in China a Lilly-discovered oral experimental drug for cardiovascular risk in patients with dyslipidemia.
Market Drivers
Increase in global geriatric population
Increase in prevalence of lifestyle diseases
Rise in acceptance of telemental health
Increase in availability of generic drugs
Market Restraints
Lack of R&D initiatives in this area.
patent expiry for some blockbuster drugs
Fewer Government initiatives taken in this direction.
Inquire Before Buying:
https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-dyslipidemia-market
Key insights in the report:
Complete and distinct analysis of the market drivers and restraints
Key Market players involved in this industry
Detailed analysis of the Market Segmentation
Competitive analysis of the key players involved
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Browse Related Report Here:
Glomerular Disease Therapeutics Market
Asia Pacific Drug Delivery Devices Market
#Dyslipidemia Market#Dyslipidemia Market share#Dyslipidemia Market size#Dyslipidemia Market trends#Dyslipidemia Market news#Dyslipidemia Market report#Dyslipidemia Market growth#Dyslipidemia Market forecast
0 notes
Text
Cell Line Development Market Analysis by Application, Revenue, Players and Vendors to 2027
Cell Line Development Market: Introduction
Cell line development is an important technology in life sciences. Stable cell lines are used for various applications including monoclonal antibody and recombinant protein productions, gene functional studies, and drug screening
Manual screening method is a traditional method used for cell line development. This method is tend to be disadvantageous as it is labor-intensive and time-consuming. Automation in tools used for cell line development is likely to replace manual methods of cell line development.
View Report : https://www.transparencymarketresearch.com/cell-line-development-market.html
Cell line development and culturing is being rapidly adopted in areas of biological drug developments for various chronic diseases, regenerative medicines such as stem cells & cell-based therapies, recombinant protein, and other cellular entities for pharmaceuticals, diagnostics, and various other industries
Key Drivers and Opportunities of Global Cell Line Development Market
Rise in focus on research & development, owing to increase in prevalence of cancer and other chronic diseases is anticipated to drive the market. Several institutes, such as Cancer Research Institute, National Cancer Institute, Advanced Centre for Treatment, Research and Education in Cancer (Cancer Research Centre [ICRC]), and NCI Community Oncology Research Program (NCORP), are engaged in research & development for cancer diagnosis and treatment. Hence, the initiative of government and non-government organizations is likely boost the growth of the market.
Mammalian cell lines are widely used as production tools for various biologic drugs. Technological advancement in cell line development in mammalian cell culturing is likely to fuel the growth of the market. For instance, according to an article published in Pharmaceuticals (Basel), the U.S. Food and Drug Administered approved 15 novel recombinant protein therapeutics from 2005 to 2011 on an average.
Advances in bioinformatics and recombinant technologies have led to development of new cell lines for synthesis or production of essential peptides, enzymes, saccharides, and other molecules which are being used in pharmaceuticals and various other industries.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart): https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75773
North America to Capture Major Share of Global Cell Line Development Market
North America is expected to account for major share of the global cell line development market due to well-established health care infrastructure and rise in government initiatives. Furthermore, adoption of innovative technologies is likely to augment the market in the region.
The cell line development market in Asia Pacific is expected to grow at a rapid pace during the forecast period, owing to increasing risk of communicable diseases, cancer, and chronic & rare diseases and surge in geriatric population. For instance, according to an article published in BioMed Central Ltd, in 2018, 2.9 million cancer deaths occurred and 4.3 million new cancer cases were recorded in China.
Key Players Operating in Global Cell Line Development Market
The global cell line development market is highly concentrated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Key players engaged in adopting new strategies are likely to drive the global cell line development market. Key players are developing new, cost-effective biologic products. This is anticipated to augment the market.
REQUEST FOR COVID19 IMPACT ANALYSIS – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75773
Major players operating in the global cell line development market are:
Merck KGaA
Selexis SA
Lonza
ATCC
Solentim Ltd.
Sphere Fluidics Limited
WuXi Biologics
Thermo Fisher Scientific
GE Healthcare
Aragen Bioscience – Contract Manufacturer
Sartorius AG
Global Cell Line Development Market: Research Scope
Global Cell Line Development Market, by Product
EquipmentBiosafety Cabinets
Incubators
Filtration / Separation Systems
Cell Culture containers
Other Ancillary Equipment
More Trending Reports by Transparency Market Research – https://www.prnewswire.com/news-releases/cholesterol-and-triglyceride-abnormalities-on-a-rise-driving-dyslipidemia-drugs-market-to-higher-trajectory-tmr-301024637.html
Reagent & Media
Global Cell Line Development Market, by Source
Mammalian
Human
Others
Global Cell Line Development Market, by Application
Biologics Production
Drug Screening/Drug Discovery
Gene Functional Study
Tissue Engineering & Regenerative Medicine
Others
Global Cell Line Development Market, by End-user
Academics & Research Institutes
Biopharmaceutical Companies
Contract Research Organization
Others
Global Cell Line Development Market, by Region
North AmericaU.S.
Canada
EuropeGermany
France
U.K.
Italy
Spain
Asia PacificChina
Japan
India
Australia & New Zealand
Rest of Asia Pacific
Latin AmericaBrazil
Mexico
Rest of Latin America
Middle East & AfricaGCC Countries
South Africa
Rest of Middle East & Africa
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
0 notes
Text
Dyslipidemia Therapeutics Future Growth Prospects and Trends Adopted by the Competitors, Regions with Forecast by 2028
The new report on the Dyslipidemia Therapeutics market provides estimations of the size of the global market and share and size of key regional markets during the historical period of 2013 – 2017. According to the report, the dyslipidemia therapeutics market is projected to record 2.5% CAGR through 2028. The business intelligence study offers readers a granular assessment of key growth dynamics, promising avenues, and the competitive landscape of the Dyslipidemia Therapeutics market.
To offer a comprehensive assessment of opportunities, the study makes a scrutiny of growth prospects in various regions. The key regions comprise the following geographical segments:
North America (U.S., Canada)
Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
Europe (Germany, Italy, France, U.K., Spain, Benelux, Russia, Rest of Europe)
Japan
APEJ (China, India, Indonesia, Thailand, Singapore, Australia & New Zealand, Rest of Asia Pacific)
MEA (GCC Countries, Turkey, Northern Africa, South Africa, Rest of Middle East & Africa)
The detailed assessments focus on, inter alia, on the regulatory and macroeconomic frameworks, prevailing pricing structure, imminent investment pockets, and emerging application areas. Taking the analysis further, the study helps readers get a better understanding of the trends characteristics of the emerging markets, including government regulations crucial to growth of such markets. Shares of major regional markets are also presented in the analysis.
Request for Sample Report with Statistical Info @
https://www.factmr.com/connectus/sample?flag=S&rep_id=2928
The study provides detailed profile of key players and their offering in the Dyslipidemia Therapeutics market, which include
· AstraZeneca
· Kowa Pharmaceuticals America, Inc.
· Merck & Co.
· Amgen
The report offers insight into the competitive dynamic in the Dyslipidemia Therapeutics market which has shaped the major strategies of each player. It also covers recent moves such as partnerships and collaborations, mergers and acquisitions, diversification and research investments, of each prominent player. The key factors that shape the entry barrier and intensity of competition in the Dyslipidemia Therapeutics market are presented in the analysis. Further, the study provides Pestle analyses of numerous players and an evaluation of how the competitive landscape will evolve over the forecast period.
On the basis of distribution channel, the global Dyslipidemia Therapeutics market report offers insights into the opportunities and new avenues of following key segments:
Hospitals
Drug
Retail
Mail Order Pharmacies
In order to analyze growth prospects in aforementioned segments in the global Dyslipidemia Therapeutics market, the study assesses demand and consumption patterns of following product outlook segments
· Market Value (US$ Mn) Forecast and Analysis
· Price Index and Price Point Assessment, by key Products
· Regional Demand Assessment
For More Detailed Information about Methodology @
https://www.factmr.com/connectus/sample?flag=RM&rep_id=2928
The global Dyslipidemia Therapeutics market report answers numerous pertinent questions, some of which are:
· What are some of the latent areas of investments in the Dyslipidemia Therapeutics market?
· Which region is expected to emerge as showing the most attractive growth rate during the forecast period and which factors will be crucial to its growth?
· What trends are likely to change the status quo of the positions held by leading players of the Dyslipidemia Therapeutics market in the not-so-distant future?
· Which product/service/technology segments holds game-changing potential to dramatically shape the competitive dynamic in the Dyslipidemia Therapeutics market?
· What are the strategies adopted by top players to retain their stronghold in the Dyslipidemia Therapeutics market?
· Which strategic moves will new entrants adopt to gain a strong foothold in the Dyslipidemia Therapeutics market?
· What are COVID-19 implication on Dyslipidemia Therapeutics market and learn how businesses can respond, manage and mitigate the risks?
How can Fact.MR Make Difference?
1. In-depth understanding of key industry trends shaping the present growth dynamics
2. Offers value chain analysis and price trend analysis of various offering of competitors
3. Offers data-drive decision to help companies decide strategies that need recalibration
4. Offers insights into areas in research and development that should attract
5. Identifies data outliers before your competitors
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: [email protected]
Blog: https://currentmarketnewsblog.wordpress.com/
Media Release: https://www.factmr.com/media-release/873/dyslipidemia-therapeutics-market
0 notes
Text
Global Generic Drugs Market
Global Generic Drugs Market was valued at US$ 273 Bn in 2017, and is expected to reach US$ 630 Bn by 2026, at a CAGR of 11 % during forecast period.
Generic drugs are manufactured and marketed after the expiry date of the patent or other exclusive rights.Generic drugs are bioequivalent to branded drugs in quality, strength, dosage form, intended use and route of administration.The important advantage of generic drugs is they are less expensive as compared to branded drugs because they are not required to repeat costly clinical trials and pay for marketing, advertising and for promotion.
In order for the company to market and sell their product they must first gain approval from the Food and Drug Administration (FDA) by submitting a New Drug Application. As per the Food and Drug Administration (FDA) rules and regulation for substitution of branded drugs, generic drugs should have the same active ingredient, same administration route, same dosage strength, and form. Nowadays, plenty of anti-diabetic, anti-hypersensitive and antibiotic drugs are available in generic formulations.
The market of the generic drug has been increased by increasing number of patent expiration of branded drugs and government initiatives. Furthermore, increasing the popularity of chronic diseases and emerging markets are responsible for the growth of generic drugs market. In addition, decreased the cost of the generic drug is acting as a most important factor for the growth of generic drug market. Despite that high competition and the shortage of drugs can hamper the growth of generic drug market. Furthermore, prescription of doctors is largely affecting the growth of generic drug market because doctors are prescribing branded drugs to their patient.
Based on the product type, a simple generic drug is an improved version of an original drug which has lost product patent protection. The product patent for the original drug will have expired or have been circumvented by the company developing the super generics.
Super generic products are referred to as added value generics, new therapeutic entities or hybrids. Super genericproducts differ from the original product in formulation or method of delivery. These products are improved formulation of a known product.
Biosimilars have the same clinical effect as a generic but are only as similar to the original branded drug as validation technologies can confirm. Biosimilar developers graduate to focus on proteins of higher complexity, requiring higher costs and even more sophisticated manufacturing, they will be challenged to adhere to established processes for proving a high degree of similarity.
Super generic drugs segment is dominating the market with high market share because it contains additional generics in low cost as compare to Biosimilars.
Based on the application, Central Nervous System segments the largest market segment covered by generic drug market. Increasing awareness about mental health, social acceptance of mentally ill patients, and increasing access to advanced healthcare options are some of the principal factors expected to drive market growth. Cost effective and easily available of drugs are expected to propel market growth during the forecast period.
Cardiovascular diseases are one of the leading causes of death worldwide. Cardiovascular covers many disease areas including heart failure, circulatory disorders, hypertension, cholesterol, dyslipidemia, angina, arrhythmias and stroke. The cardiovascular segment covers more than 15% of global generic drug market due to a number of patent expiries of cardiovascular drugs.
Growth in the overall global population and aging demographics is proving to be beneficial for the overall
healthcare sector and generic drug manufacturers.
Geographically, North America is dominating the generic drug market attribute to high demand and increasing the prevalence of chronic diseases.
Asia-Pacific is expected to show significant growth during the forecast period. From Asia Pacific region many of patients are travels toward to North America to take a better treatment. In the Asia Pacific, India and China countries are leading in the generic drug market.
for more information visit:https://www.maximizemarketresearch.com/market-report/global-generic-drugs-market/25900/
Scope of Global Generic Drugs Market:
Global Generic Drugs Market, by Product Type
• Simple Generics
• Super Generics
• Biosimilars
Global Generic Drugs Market, by Application
• Cardiovascular
• Anti-Infective
• Anti-Arthritis
• Central Nervous System
• Anti-Cancer
• Respiratory
• Others
Global Generic Drugs Market, by Region
• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America
Some Key Players Operating the Global Generic Drugs Market
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Actavis Pharmaceuticals
• Sandoz
• Sun Pharma
• Par Pharmaceuticals
• Endo Pharmaceuticals
• Lupin Pharmaceuticals
• Dr Reddy’s
• Pfizer
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: Lumawant Godage
Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: [email protected]
Address : Pune, Maharashtra 411051, India.
Contact: +919607195908
0 notes
Text
Global Peripheral Arterial Disease (PAD) Therapeutics Industry
New Post has been published on https://vizrelease.com/press-release/1270027/
Global Peripheral Arterial Disease (PAD) Therapeutics Industry
reportlinker.com/p0960424/Global-Peripheral-Arterial-Disease-PAD-Therapeutics-Industry.html#utm_source=prnewswireandutm_medium=prandutm_campaign=Therapy
I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Low Awareness and Limited Pharmaceutical Options Typify PAD
Market II-1
Critical Limb Ischemia – An Insight II-2
Growing Incidence, Rooted in Aging and Lifestyle- Related
Issues, Drives the PAD Market II-2
Inflating Elderly Population Forms Basis for PAD Therapeutics
Market II-3
Table 1: 2011 Global Population Statistics for the 65+ Age
Group (includes corresponding Graph/Chart) II-4
High Costs – A Cause of Concern II-5
Anti-Platelet Drugs: Spearheading the Battle against PAD II-5
Plavix Set to Lose Ground following Patent Expiry II-5
A Peek into the History of Palvix II-6
Table 2: Plavix Stands Second in the Global Pharma Industry:
Ranking of Global Top 20 Pharma Brands in 2010 in Terms of
Sales (USD Million) (includes corresponding Graph/Chart) II-7
Table 3: Global Sales of Plavix: 2009 and 2010 (in US$
Millions) (includes corresponding Graph/Chart) II-8
Effient Falters as Concerns with Side-Effects Grow II-8
Will Brilinta be the New Plavix? II-9
Cholesterol-Lowering Drugs: A Key Weapon in the Anti-PAD Arsenal II-9
Gene Therapy Fails to Deliver on Initial Promise II-10
Hopes Pinned on Stem Cell Therapy to Revolutionize PAD Treatment II-10
Placenta-derived Stem Cell Therapy: A Promising Treatment for
PAD II-10
PAD Holds Potential to Spawn Innovation and Growth in Medical
Devices Market II-11
deCODE genetics Discovers SNP Linking Susceptibility to Major
Vascular Diseases II-11
Myth Busted as PAD Revealed to Target Greater Numbers of
Females than Males II-11
2. AVAILABLE DRUGS FOR PHARMACOLOGICAL TREATMENT II-12
Plavix (Clopidogrel) II-12
Prasugrel (Effient) II-12
Ticagrelor (Brilinta) II-12
Cilostazol (Pletal(R)) II-13
3. PERIPHERAL ARTERIAL DISEASE (PAD) – AN OVERVIEW II-14
Peripheral Arterial Disease: Understanding the Stealthy Peril II-14
Causes of PAD II-14
Tobacco Use II-14
Diabetes II-14
Dyslipidemia II-14
Hypertension II-15
Causes of PAD in Lower Extremities II-15
Atherosclerosis II-15
Blood Clotting II-15
Link Established between Depression and PAD II-15
Ethyl-EPA Intake Proves Favorable for PAD Sufferers II-16
PAD Risk Factors II-16
Symptoms of PAD II-17
Claudication II-17
Rest Pain II-17
Other Symptoms II-17
Prognosis of PAD II-17
Diagnosis of PAD II-18
Ankle Brachial Index (ABI) II-18
Ankle-Brachial Index and Associated Severity of Peripheral
Arterial Disease II-19
Magnetic Resonance Angiography (MRA) and CT Scan II-19
Control of PAD II-19
Classification of PAD Severity II-20
Treatment for PAD II-20
Lifestyle Changes II-20
Medication II-21
Surgery II-21
Methods for Avoiding PAD Complications II-22
Conclusion II-22
4. CLINICAL STUDIES/CORPORATE INITIATIVES II-23
Shire Plc Acquires Pervasis Therapeutics II-23
Aldagen Inc.’s ALD-301 Presents Positive Phase I/II Results in
Critical Limb Ischemia Clinical Study II-23
Cytokinetics Begins Phase IIa EoE Clinical Trial of Ck-2017357
in Patients with PAD and Claudication II-24
NV1FGF Fails to Demonstrate Efficacy in Phase 3 Trials II-24
Pervasis Commences Second Clinical Program Aimed at PAD II-25
Taiwan Liposome and Ildong Pharm Tie Up to Market ProFlow for PAD II-25
miRagen Therapeutics Enters into Licensing Agreement with t2cure II-25
Pluristem Therapeutics Presents Positive Results for PLX-PAD II-26
Unremarkable Statistical Results from Phase II Clinical Study
of 6R-BH4 in Peripheral Arterial Disease II-26
Aastrom Biosciences Reports Treatment of Final Patient in
RESTORE-CLI Clinical Trial II-27
Aastrom Biosciences Receives Fast Track Designation from FDA
for Phase III CLI Program II-27
Diffusion Pharmaceuticals Achieves Success in Phase I/II
Clinical Trial of Trans Sodium Crocetinate in PAD II-27
ReNeuron Group Provides Positive Results on ReN009 Stem Cell
Therapy for PAD II-28
AnGes MG Receives FDA Approval for Late Stage Trial of PAD
Therapeutic II-28
Effient Bags Approval in Europe II-28
5. FOCUS ON SELECT GLOBAL PLAYERS II-29
AstraZeneca Plc. (UK) II-29
CardioVascular BioTherapeutics, Inc. (US) II-29
Cytokinetics, Inc. (US) II-30
Diffusion Pharmaceuticals LLC (US) II-30
Eli Lilly and Company (US) II-30
miRagen Therapeutics, Inc. (US) II-31
ReNeuron Group PLC (UK) II-32
Sucampo Pharmaceuticals, Inc. (US) II-33
TCA Cellular Therapy, LLC (US) II-33
TheraVasc, Inc. (US) II-33
6. GLOBAL MARKET PERSPECTIVE II-35
Table 4: World Recent Past, Current and Future Analysis for
Peripheral Arterial Disease Therapeutics by Geographic
America, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) II-35
Table 5: World Historic Review for Peripheral Arterial Disease
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) II-36
Table 6: World 15-Year Perspective for Peripheral Arterial
Disease Therapeutics by Geographic Region/Country – Percentage
Years 2004, 2011, and 2018 (includes corresponding
Graph/Chart) II-37
III. MARKET
A.Market Analysis III-1
Current and Future Analysis III-1
Market Potential III-1
Market Overview III-2
PAD Awareness Imperative for Market Growth III-2
Table 7: US Pharmaceutical Market (2007-2011): Sales in
US$ Millions for Lipitor, Plavix, Nexium, Abilify, Advair
Diskus, Seroquel, Singulair, Crestor, Cymbalta, Humira,
and Others (includes corresponding Graph/Chart) III-3
Plavix(R) Granted Extension on US Market Exclusivity III-4
Generics Set to Steal Market Share from Plavix III-4
Repeat PAD Hospitalizations Contribute to Sky-High
Treatment Costs III-4
Select Regional Players III-4
B.Market Analytics III-7
Table 8: The US Recent Past, Current and Future Analysis for
Peripheral Arterial Disease Therapeutics Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-7
Table 9: The US Historic Review for Peripheral Arterial
Disease Therapeutics Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-8
A.Market Analysis III-9
Low Awareness and Knowledge Characterize the Canadian PAD
Market III-9
B.Market Analytics III-9
Table 10: Canadian Recent Past, Current and Future Analysis
for Peripheral Arterial Disease Therapeutics Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) (includes
corresponding Graph/Chart) III-9
Table 11: Canadian Historic Review for Peripheral Arterial
Disease Therapeutics Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-10
A.Market Analysis III-11
Current and Future Analysis III-11
Up to 3.2 Million West-European Denizens Caught in the Web
of Critical Limb Ischemia III-11
Europe III-11
Plavix(R) Faces Generic and Branded Competition in Europe III-11
Table 12: Western Europe Plavix Comparative Sales 2010 and
2011 in US$ Millions III-12
Table 13: Sales of Plavix across the EU (2011): Percentage
Graph/Chart) III-12
Strategic Corporate Development III-12
B.Market Analytics III-13
Table 14: European Recent Past, Current and Future Analysis
for Peripheral Arterial Disease Therapeutics by
Europe Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) III-13
Table 15: European Historic Review for Peripheral Arterial
Annual Sales Figures in US$ Million for Years 2004 through
2009 (includes corresponding Graph/Chart) III-14
Table 16: European 15-Year Perspective for Peripheral
Arterial Disease Therapeutics by Country/Region – Percentage
2018 (includes corresponding Graph/Chart) III-15
A.Market Analysis III-16
Current and Future Analysis III-16
Sanofi – A Leading French Player III-16
B.Market Analytics III-17
Table 17: French Recent Past, Current and Future Analysis
for Peripheral Arterial Disease Therapeutics Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-17
Table 18: French Historic Review for Peripheral Arterial
Disease Therapeutics Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-18
A.Market Analysis III-19
Current and Future Analysis III-19
Strategic Corporate Development III-19
Select Regional Players III-20
B.Market Analytics III-21
Table 19: German Recent Past, Current and Future Analysis
for Peripheral Arterial Disease Therapeutics Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-21
Table 20: German Historic Review for Peripheral Arterial
Disease Therapeutics Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-22
Market Analysis III-23
Table 21: Italian Recent Past, Current and Future Analysis
for Peripheral Arterial Disease Therapeutics Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-23
Table 22: Italian Historic Review for Peripheral Arterial
Disease Therapeutics Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-24
A.Market Analysis III-25
Current and Future Analysis III-25
Market Overview III-25
Leading Players III-25
B.Market Analytics III-26
Table 23: UK Recent Past, Current and Future Analysis for
Peripheral Arterial Disease Therapeutics Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-26
Table 24: UK Historic Review for Peripheral Arterial Disease
Therapeutics Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-27
Market Analysis III-28
Table 25: Spanish Recent Past, Current and Future Analysis
for Peripheral Arterial Disease Therapeutics Analyzed with
Annual Sales Figures in US$ Million for Years 2010 through
2018 (includes corresponding Graph/Chart) III-28
Table 26: Spanish Historic Review for Peripheral Arterial
Disease Therapeutics Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-29
A.Market Analysis III-30
Current and Future Analysis III-30
Select Regional Players III-30
B.Market Analytics III-31
Table 27: Rest of Europe Recent Past, Current and Future
Analysis for Peripheral Arterial Disease Therapeutics
Analyzed with Annual Sales Figures in US$ Million for Years
2010 through 2018 (includes corresponding Graph/Chart) III-31
Table 28: Rest of Europe Historic Review for Peripheral
Arterial Disease Therapeutics Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2004 through
2009 (includes corresponding Graph/Chart) III-32
A.Market Analysis III-33
Current and Future Analysis III-33
A Snapshot of Indian Market Opportunity III-33
Strategic Corporate Development III-33
Select Regional Players III-34
B.Market Analytics III-35
Table 29: Asia-Pacific Recent Past, Current and Future
Analysis for Peripheral Arterial Disease Therapeutics
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-35
Table 30: Asia-Pacific Historic Review for Peripheral
Arterial Disease Therapeutics Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2004 through
2009 (includes corresponding Graph/Chart) III-36
Market Analysis III-37
Table 31: Latin American Recent Past, Current and Future
Analysis for Peripheral Arterial Disease Therapeutics
Analyzed with Annual Sales Figures in US$ Million for Years
2010 through 2018 (includes corresponding Graph/Chart) III-37
Table 32: Latin American Historic Review for Peripheral
Arterial Disease Therapeutics Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2004 through
2009 (includes corresponding Graph/Chart) III-38
6. REST OF WORLD III-39
A.Market Analysis III-39
Current and Future Analysis III-39
Select Regional Players III-39
B.Market Analytics III-40
Table 33: Rest of World Recent Past, Current and Future
Analysis for Peripheral Arterial Disease Therapeutics
Analyzed with Annual Sales Figures in US$ Million for Years
2010 through 2018 (includes corresponding Graph/Chart) III-40
Table 34: Rest of World Historic Review for Peripheral
Arterial Disease Therapeutics Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2004 through
2009 (includes corresponding Graph/Chart) III-41
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 50 (including Divisions/Subsidiaries – 53)
SOURCE Reportlinker
0 notes
Text
Dyslipidemia Therapeutics Market: Present Scenario and the Growth Prospects with Forecast 2026
Consolidation of Multinationals Continues, With Nearly 60% Shares
Nature of the global dyslipidemia therapeutics market remains consolidated, with leading players accounting for approximately 60% shares. Co-promotion of dyslipidemia therapeutic drugs with local or regional players, aggressive marketing, new product launches, and high investments in research and development of novel drugs are the go-to strategies being employed by leading dyslipidemia therapeutics market players to expand their global footprint.
Read Report Overview:
https://www.factmr.com/report/2928/dyslipidemia-therapeutics-market
Meanwhile, local players continue to focus on expanding their manufacturing capacity to meet the growing demand for dyslipidemia drugs in the regional market. Additionally patent expiration of a multiple dyslipidemia drugs is expected to open up new opportunities for the regional players in terms of drug discovery and development. Some of the notable highlights of the dyslipidemia therapeutics market have been listed below:
To capitalize on the growing demand for dyslipidemia drugs in the Chinese market, AstraZeneca entered into a strategic alliance with Luye Pharma that bestowed the company with exclusive rights to promote Lyue Pharma’s Xuezhikang Capsules – a drug that has been identified as the first-line blood management medication by the Chinese government.
As a part of its marketing strategy, Kowa Pharmaceuticals America, Inc. launched the “Take Cholesterol to Heart” campaign, to promote the efficacy of statins in the treatment of dyslipidemia. The company is partnering with Hollywood stars and TV actors for the campaign.
Request Discount-
https://www.factmr.com/connectus/sample?flag=D&rep_id=2928
Sanofi, a French pharmaceutical company launched Praluent, a novel dyslipidemia therapy in Korea in collaboration with Aventis Korea. This new therapy will work towards inhibiting the binding of PCSK9 to low-density lipoprotein receptors (LDLRs).
In January 2019, Amgen received approval for its proprietary drug Repatha from the National Medical Products Administration (NMPA) in China. The drug will be the first PCSK9 inhibitor medication for adults in China where the prevalence of dyslipidemia has increased in the recent past, triggering the demand for dyslipidemia therapeutics in the region.
Recent research has linked the presence of high levels of lipoprotein (a) cholesterol (Lp[a]-C), and low levels of lipoprotein cholesterol subparticle 3 (HDL3C), identifying these as novel biomarkers to diagnose the severity of coronary artery disease (CAD) in patients. The results have the potential to drive advancements in the dyslipidemia therapeutics market.
The report on the dyslipidemia therapeutics market also provides a detailed analysis of the key players operating in the dyslipidemia therapeutics market. The dyslipidemia therapeutics market report provides a comprehensive profile of leading players functioning in the dyslipidemia therapeutics market which include Merck & Co., Pfizer, Novelion Therapeutics, Mylan, Abbott Laboratories, and Novartis AG.
Get Report Sample:
https://www.factmr.com/connectus/sample?flag=S&rep_id=2928
Efficacy-driven Novel Approaches for Dyslipidemia Therapeutics
Combination therapies for dyslipidemia have gained a marked significance in the recent past, deemed as an efficient solution to offset concerns regarding varied effectiveness of statins with respect to affected patients. Complementary mechanisms in combination with statins have emerged as a novel measures to ebb low-density lipoprotein levels – a key aspect enhancing the risk of dyslipidemia. Recent approval of novel drugs such as PCSK9 antibodies by regulatory authorities such as China’s National Medical Products Administration (NMPA), and The UK’s National Institute for Health and Care Excellence (NICE), alludes a rise in prevalence of novel drugs for dyslipidemia therapeutics in the near future.
Medical researchers’ efforts towards the identification of new gene therapies for treatment of Mendelian lipid disorders can further open gateways to efficient dyslipidemia therapeutics and management. Additionally, leading players in the dyslipidemia therapeutics market are taking efforts to improve the overall efficacy of their dyslipidemia therapeutic drugs and are investing heavily in research and development of novel medication to target triglycerides and other lipoproteins.
0 notes
Text
Dyslipidemia Drugs Market is Expected to Demonstrate a CAGR of 11.4% During the Forecast Period of 2014 to 2022
The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and immunosuppressant along with multiple therapies. The prominent players in the market are also collaborating with diagnostic laboratories so as to increase awareness level of the population in regards to the availability of options for treatment for the invasive diseases.
Some of the key players operating in the global glioblastoma multiforme market are Celldex Therapeutics, Inc., Abbvie, Inc., Brostol-Myers Squibb Co., F.Hoffman La Roche, and Exellixis, Inc. During 2013, F.Hoffman La Roche was the most efficient and promising source of glioblastoma multiforme treatment all because of “brain shuttle” which was the company’s novel drug delivery system.
Ask for Discount on Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4807
The global glioblastoma multiforme treatment market is expected to rise at a healthy CAGR of 11.4% during the forecast period of 2014 to 2022. The global market is expected to attain a valuation of $US0.91 bn by the end of 2022. The global glioblastoma multiforme product segment is led by bevacizumab product and is expected to rise in demand during the forecast period as it is more efficient than temozolomide. Geographically, the glioblastoma multiforme treatment market is led by North America. This region is consuming larger share in the market is expected to dominate the global market during the forecast period.
Rise in Awareness Regarding Cancer and Novel Therapies to Boost Global Glioblastoma Multiforme Market
The global glioblastoma multiforme treatment market is rising rapidly owing to increasing geriatric population. Rise in awareness about the brain tumor itself is generating demand for the glioblastoma multiforme treatment market. Various organizations across the globe are spreading awareness about the introduction of novel therapies thus, boosting the growth of market. Rise of modern techniques for diagnosis and rapid development of drug delivery technologies are likely to supplement the growth of the market. Increasing support from government to conduct research and development across the globe is adding fuel to the market.
Buy Now : https://www.transparencymarketresearch.com/checkout.php?rep_id=4807<ype=S
Development of healthcare infrastructure is one of the reasons for market growth. The unmet medical needs require desperate novel treatment strategies thus, generating demand for the market. The glioblastoma multiforme treatment pipeline include a mix of immunotherapy, small molecules, biological therapeutics and other types of therapeutics that makes it ideal for treatment of disease. Advanced introduced in molecular biology and gene technology also has the potential to provide lucrative novel possibilities for effective treatment of diagnosed patients.
Recurrence of Disease Likely to Hamper Market Growth
The global glioblastoma multiforme treatment market is anticipated to face certain restrains in the market that might hamper the growth of the market. The current FDA approved treatments are likely to cause neurotoxicity in patients which might stagger the growth of market. This treatment is not resistance against DNA modifying agents thus, hampering its growth in the market. The migration of malignant cells inside the adjacent brain tissues increasing the complexity of surgery is also affecting the market. The treatment options lack efficiency as the mortality rate is characterized by rapid growth and poor survival rates. Survival rates of glioblastoma is 8.7% even after glioblastoma multiforme treatment being in the healthcare sector since last few years. The modalities have worked little to decrease the overall mortality rate of patients. Recurrence of the disease, invasiveness of GBM, and resistance of glioma stem cell against conventional modalities are other potential factors that will hamper the growth of the global glioblastoma multiforme treatment market.
0 notes
Text
HIV-associated Lipodystrophy Market Poised to Expand at a Robust Pace by 2025
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities, including insulin resistance, and dyslipidemia. The HIV-associated lipodystrophy groups together different clinical conditions, which are lipoatrophy and lipoaccumulation. Lipoatrophy is associated with subcutaneous fat loss, whereas lipoaccumulation is the increase in visceral fat. In certain cases, HIV-associated lipodystrophy may occur as a combination of these two conditions; thus, its treatment and prevalence measurement are difficult.
The global HIV-Associated Lipodystrophy Market is witnessing unprecedented dynamics. Several research studies are directed toward finding out the link between the two mechanisms of lipodystrophy in such a way that a single mechanism will can occur for redistribution of fat. Improving healthcare infrastructure and increasing incidence rates of HIV/AIDS patients globally are expected to drive the growth of the global HIV-associated lipodystrophy market. However, lower adoption of therapeutic treatment and demand for constant nutritional supply from patients is anticipated to restrain the growth of the global HIV-associated lipodystrophy market.
The global HIV-associated lipodystrophy market has been segmented based on lipodystrophy type, therapeutic class, and distribution channels. On the basis of lipodystrophy type, the market has been classified into lipoatrophy and lipoaccumulation. In terms of therapeutic class, the market is divided into anabolism modulators, insulin resistance modulators, mitochondrial antioxidants (L-carnitine), and other miscellaneous metabolic agents.
Request to View Brochure of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22925
Anabolism modulators are further bifurcated into growth hormones and anabolic steroids. Insulin resistance modulators can be sub-segmented into metformins, thiazolidinediones, and others. Growth hormones are widely used for the treatment of HIV-associated lipodystrophy due to their efficacy. Based on distribution channels, the global HIV-associated lipodystrophy market is categorized into hospital pharmacy stores, retail pharmacy stores, and online pharmacies. Hospital pharmacy stores are expected to account for higher market share due to their ease of connectivity, and trend of utilization of newly advanced products among end-users including physicians and patients.
There is a lack of evidence-based strategies for the treatment of HIV-associated lipodystrophy. The treatment switch between the two lipodystrophy conditions, along with HIV drugs that possess lower mitochondrial toxicity, is an emerging trend in the global HIV-associated lipodystrophy market. There is a large patient pool in emerging countries, where lower drug affordability is a major challenge for market penetration of HIV-associated lipodystrophy therapeutics. Thus, the introduction of affordable drugs by local manufacturers serves as a major opportunity in the global HIV-associated lipodystrophy market. However, the other treatment options such as cosmetic surgeries also arrests the growth of the global HIV-associated lipodystrophy market.
Request to View ToC of the report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=22925
On the basis of geography, the global HIV-associated lipodystrophy market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to grow at a high CAGR owing to factors like large patient pool, increasing demand for low cost drugs, rising awareness of the treatment options for HIV-associated lipodystrophy, and adoption of better healthcare facilities. North America is projected to dominate the global HIV-associated lipodystrophy market due to increasing adoption of new and technologically advanced products, high per capita health expenditure, and substantial investments in research and development for efficient treatment options.
Key players in the global HIV-associated lipodystrophy market are Novelion Therapeutics Inc., Theratechnologies Inc., Gilead Sciences Inc., GlaxoSmithKline plc (Viiv Healthcare Group of Companies), AbbVie Inc., Bristol-Myers Squibb Company, and AstraZeneca plc, among others.
0 notes
Text
Global Dyslipidemia Therapeutics Market Size, Trends, Share, Key Player & Forecast until 2023
A Comprehensive research study conducted by KD Market Insights on " Dyslipidemia Therapeutics Market – By Product Type (Low-density Lipoproteins (LDL), Triglycerides), By Drug Class (Statins, Non-Statins, Combinations Drugs), By Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Stores, Mail Order Pharmacies) & Global Market Size, Trends, Share & Forecast 2018-2023" report offers extensive and highly detailed historical, current and future market trends in the global and regional/market. The Dyslipidemia Therapeutics Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.
Global Dyslipidemia Therapeutics market witnessed a market value of USD XX Million in 2017 and is estimated to reach USD XX million in 2023, registering a compound annual growth rate (CAGR) of XX% between 2017 and 2023. The market research report demonstrates market dynamics which includes growth drivers, restraining factors and opportunities and trends spearheading current nature and future status of this market. Our general approach is to target several individuals with specific questions that we believed would satisfy our research objective. Further, to speed up the data collection process, we employed an online survey, delivered via email. The research team analyzed the results to identify potential opportunities and risks for the market.
Request for Sample @ https://www.kdmarketinsights.com/sample/3070
In addition, the report offers recent industry activities and value chain analysis for the Dyslipidemia Therapeutics Market. Moreover, Porter’s Five Forces analysis demonstrates the five forces which include buyers bargaining power, suppliers bargaining power, the threat of new entrants, the threat of substitutes, and degree of competition in Dyslipidemia Therapeutics Market. Along with figures and tables, a market attractiveness and BPS analysis has been provided for every segment in the report.
The report analyses the market by geographies i.e. North America, Europe, Asia Pacific, Latin America & Middle East & Africa. Further, the geographies are fragmented into the country and regional groupings:
- North America (U.S. & Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, Argentina and Rest of Latin America)
- Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa)
Segmentation
The research offers a comprehensive analysis of global Dyslipidemia Therapeutics market with respect to following sub-markets:
Based on Product Type:
- Low-density Lipoproteins (LDL)
- Triglycerides
Based on Drug Class:
- Statins
- Non-Statins
- - - PCSK9 inhibitors
- - - Cholesterol absorption inhibitors
- - - Bile Acid resins
- - - Fibrate
- - - Others
- Combinations Drugs
Based on Distribution Channel:
- Hospitals Pharmacies
- Drug Stores
- Retail Stores
- Mail Order Pharmacies
Competitive Landscape
The report includes profiles of leading companies in the global Dyslipidemia Therapeutics market. Some of the key players profiled include:
- AstraZeneca
- Kowa Pharmaceuticals America, Inc
- Merck & Co
- Pfizer
- Amgen
- Sanofi
- Novelion Therapeutics
- Mylan
- Abbott Laboratories
- Novartis AG
- Other Major & Niche Key Players
Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/dyslipidemia-therapeutics-market
Table of Contents:
Research Methodology
Market Definition and List of Abbreviations
1. Executive Summary
2. Growth Drivers & Issues in Global Dyslipidemia Therapeutics Market
3. Global Dyslipidemia Therapeutics Market Trends
4. Opportunities in Global Dyslipidemia Therapeutics Market
5. Recent Industry Activities, 2017
6. Porter's Five Forces Analysis
7. Market Value Chain and Supply Chain Analysis
8. Global Dyslipidemia Therapeutics Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
9. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Product Type
9.1. Introduction
9.2. Market Attractiveness, By Product Type
9.3. BPS Analysis, By Product Type
9.4. Low-density Lipoproteins (LDL) Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
9.5. Triglycerides Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
10. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Drug Class
10.1. Introduction
10.2. Market Attractiveness, By Drug Class
10.3. BPS Analysis, By Drug Class
10.4. Statins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
10.5. Non-Statins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
10.5.1. PCSK9 inhibitors Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
10.5.2. Cholesterol absorption inhibitors Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
10.5.3. Bile Acid resins Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
10.5.4. Fibrate Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
10.5.5. Others Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
10.6. Combinations Drugs Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
11. Global Dyslipidemia Therapeutics Market Segmentation Analysis, By Distribution Channel
11.1. Introduction
11.2. Market Attractiveness, By Distribution Channel
11.3. BPS Analysis, By Distribution Channel
11.4. Hospitals Pharmacies Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
11.5. Drug Stores Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
11.6. Retail Stores Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
11.7. Mail Order Pharmacies Market Size (USD Million), Forecast & Y-o-Y Growth Analysis, 2017-2023
Continue…
Check for Discount @ https://www.kdmarketinsights.com/discount/3070
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.
Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: [email protected]
Website: www.kdmarketinsights.com
#Dyslipidemia Therapeutics Market#Dyslipidemia Therapeutics Market Size#Dyslipidemia Therapeutics Market Trends#Dyslipidemia Therapeutics Market Share#Dyslipidemia Therapeutics Market growth
0 notes
Last Seen Blogs
kalasakht-blog
Untitled
bluelobster10
A Blue Lobster Safe Space
rwrb-fests
RWRB Fests
dana-janelle
Sometimes Danelle